ZNF385B and ductal breast carcinoma in situ: The validation via the microarray GSE21422 demonstrated that ZNF385B expression levels in tumor tissues, which included invasive ductal carcinoma (ICD) and ductal carcinoma in situ (DCIS), were lower than those in healthy samples (p = 0.03; Figure 5(a)).